Email :info@anzen.co.inCall Us : +91 33 24549650

Efficacy of Drotaverine HCL as Antispasmodic Drug | Anzen Exports

October 16, 2020by Anzen_Exports0

INN is another name of Drotaverine Antispasmodic drug
Drotaverine is a highly effective anti-spasmodic drug. This drug is generally used in alleviating pain in the renal colic or abdominal area, however, it is devoid of anticholinergic effects. It significantly decreases pain frequency and severity. Globally clinicians and patients approved Drotaverine HCL as better compared to drugs of a similar mechanism. (1)

INN is another name for this drug. It is structurally connected to papaverine and is an inhibitor of phosphodiesterase 4, which acts as a dose-dependent analgesic.

Chemical Formula – C24H31NO4

Weight – Average: 397.5072mg

Monoisotopic: 397.225308485 (2)

What is Spasm Pain?

Spasm pain is related to muscles. When one or more muscles make the involuntary movement or forcibly contract, but cannot relax then it results in spasm pain. It may be caused by stress, infection, inflammation or any blockage. It is often referred to as cramps. Antispasmodic tablets act only as a relief in this case.

Uses of Drotaverine

The antispasmodic uses of this drug are for:

  • Menstrual pain
  • Abdominal pain
  • Pain for kidney stone
  • Pain caused by a biliary stone
  • Gastro-intestinal colicky pain
  • Irritable bowel syndrome
Mechanism of Action

Drotaverine HCL dosage inhibits phosphodiesterase hydrolysing cAMP (Cyclic Adenosine Monophosphate), which in turn increases the concentration of the cAMP. This decreases the calcium (Ca) uptake capacity of the cell resulting in a change of distribution of Ca among the various cells.

This antispasmodic drug blocks the allosteric calcium channel up to a certain extent. It has a high bioavailability variable, i.e. maximum portion of the drug enters into the circulation system of the body and works effectively. With a hepatic metabolism, INN has a half-life of 7 to 12 hours. (3)

Side Effects

Some common side effects are:

  • Nausea
  • Vomiting
  • Vertigo
  • Dryness in mouth
  • Drop in blood pressure
  • Dizziness (4)
Contraindications

It is contraindicated in patients with:

Always share the health history with thedoctor before taking any medicine.

Dosage Details

Patients under 1-5 years may take 20mg Drotaverine Hydrochloridetablets 3 to 4 times daily. People between the ages of 6 – 12 years may take 40mg three times a day. 80mg is the maximum dosage that can be taken by a patient of any age above 12 years. Consult a doctor before taking any medicine. Avoid over-the-counter drugs or painkillers.

Active Pharmaceutical Ingredients

API is the active chemical substance that makes a drug functionally effective on the human body. Anzen Exports is an API exporter based in India. It exports API to 70 countries across the world. Throughout 29 years of operations, it has created a strong network with the finest API manufactures across India. It is dedicated to exporting quality products at competent pricing.

To inquire about Drotaverine HCL uses and availability one may connect with the sales team.

Disclaimer:

Anzen Exports blog posts are based just on our research from cited websites. To be best informed, we advise to consult a doctor about an ingredient or medicine prior to taking it.

Sources:

  1. NCBI
    Website – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271014/
    Date – Nov 2014
  2. Drug Bank
    Website – https://go.drugbank.com/drugs/DB06751
  3. Drug Bank
    Website – https://go.drugbank.com/drugs/DB06751
  4. 1mg
    Website – https://www.1mg.com/generics/drotaverine-211823#:~:text=Drotaverine%20is%20an%20anti%2Dspasmodic,smooth%20muscles%20in%20the%20abdomen.&text=Drotaverine%20helps%20relieve%20pain%20due,duration%20suggested%20by%20your%20doctor.

Leave a Reply

Your email address will not be published. Required fields are marked *


Headquarters

Anzen Exports

20C Hazra Road, Kolkata 700026, West Bengal, India.info@anzen.co.in

+91 33 24549650

SOCIAL MEDIA

Follow Our Activity On





GET IN TOUCH

Subscribe to our Newsletter